Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, cash reserves at Bellevue Life Sciences Acquisition Corp fell by 109.08k. Cash Flow from Financing totalled 34.54m or -- of revenues. In addition the company used 818.77k for operations while cash used for investing totalled 33.83m.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 2.69 |
---|---|
Tangible book value per share | 2.69 |
More ▼
Balance sheet in USDView more
Current ratio | 0.0488 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.0989 |
---|---|
Total debt/total capital | 0.09 |
More ▼